In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's D-mab: The New EPO

Executive Summary

D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.
Advertisement

Related Content

Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe
Amgen's Prolia Gains First Regulatory Win: Market Approval in Europe
Commercial Models: Change Is Underfoot In Europe, Too
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Pricing Experiments: Pharmas Get Creative in Germany
Pricing Experiments: Pharmas Get Creative in Germany
Actelion Follows Innovation into GP Markets
Living With REMS: The New Regulatory Model Meets Commercial Reality
Can Amgen Find a New Engine?
Can Amgen Find a New Engine?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel